NanoViricides, Inc. Completes $8.65M Equity Offering via Olshan Client Aegis Capital Corp.
Olshan Frome Wolosky LLP acted as counsel to Aegis Capital Corp., as sole bookrunner and representative of the several underwriters, in NanoViricides, Inc.’s (NYSE American: NNVC) $8.65 million follow-on equity public offering of 2,875,000 shares of common stock, including the underwriters’ full exercise of their 375,000 over-allotment option. NanoViricides is a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform. NanoViricides believes this financing provides valuable capital to help the company advance its drug pipeline into human clinical trials. NanoViricides anticipates filing an IND with the US FDA to advance NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication.
The Olshan Frome team was led by corporate partner Spencer G. Feldman and included corporate partner Kenneth A. Schlesinger and counsel Jason D. Cabico.